Abstract
Diabetes mellitus is a chronic disease requires continuous therapy by professional health workers and self-care management from the patients. To support this, diabetic patient who seek treatment at the primary healthcare facilities is recommended to join The Chronic Disease Management Program (Prolanis). During the Covid-19 pandemic, the frequency of diabetic-related prolanis activities became less monitored, especially regarding the accuracy of using antidiabetic oral (ADO). A quasi-experimental study was conducted through drug education by pharmacists to determine the effect of such education on clinical outcomes, namely the patient's glycosylated hemoglobin (HbA1c) levels. The results showed that there was a decrease in HbA1c levels (1.31%) in the intervention group (n=7) and an increase in HbA1c (0.51%) in the control group (n=17; p=0.078). Eventhough it was not statistically significant due to limited research subjects, education on the proper use of ADO can reduce HbA1c levels in diabetic patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
